Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Neal Flomenberg Sells 14,639 Shares

Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 14,639 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $1.28, for a total transaction of $18,737.92. Following the sale, the insider now directly owns 4,239,663 shares in the company, valued at approximately $5,426,768.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Neal Flomenberg also recently made the following trade(s):

• On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The stock was sold at an average price of $1.10, for a total transaction of $97,370.90.

Tevogen Bio Price Performance

NASDAQ TVGN traded down $0.08 during trading hours on Monday, reaching $1.06. The stock had a trading volume of 620,487 shares, compared to its average volume of 5,077,555. Tevogen Bio Holdings Inc. has a 52-week low of $0.26 and a 52-week high of $7.61. The stock has a fifty day moving average of $1.36 and a 200 day moving average of $1.16.

Institutional Trading of Tevogen Bio

Several large investors have recently made changes to their positions in TVGN. HGC Investment Management Inc. purchased a new stake in Tevogen Bio in the third quarter valued at $82,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tevogen Bio in the 4th quarter valued at about $38,000. Northern Trust Corp boosted its stake in shares of Tevogen Bio by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after buying an additional 13,595 shares during the last quarter. Barclays PLC grew its holdings in Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after acquiring an additional 12,847 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Tevogen Bio by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after acquiring an additional 16,695 shares in the last quarter.

Remove Ads

Analyst Ratings Changes

Separately, D. Boral Capital initiated coverage on Tevogen Bio in a research note on Tuesday, March 4th. They issued a "buy" rating and a $10.00 target price for the company.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.